I am more optimistic about NASH than NP (at least publicly). Liver fibrosis is directly caused by inflammation boosted by the CCL5 ligand. Leronlimab blocks CCR5 and those bad CCL5's so no signaling pathway and inflammation doesn't develop.

There are no current anti-fibrosis NASH drugs approved and it seems the best (maybe only) viable path are CCR5 blockers. Yes other CCR5 blockers will do the same as ours, but once again we have the upper hand in lack of side effects.